Benzinga | Dec 18, 2020 07:07AM EST

Bruker Launches FluoroType SARS-CoV-2/Flu/RSV PCR Panel In Europe With CE-IVD Mark

* Winter four-plex panel detects clinically most important respiratory viruses SARS-CoV-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)

* Validation with nasopharyngeal swabs and oropharyngeal swabs for highest sensitivity

* Saliva sampling option convenient for patients, while also achieving high PCR sensitivity; saliva samples do not require extraction and enable a faster, resource-effective workflow

Bruker Corporation (NASDAQ:BRKR) today announced the launch of the FluoroType SARS-CoV-2/Flu/RSV winter four-plex PCR panel, which enables the sensitive and simultaneous detection of the SARS-CoV-2 virus, of both influenza A and B viruses, as well as of the respiratory syncytial virus (RSV). In the winter season, multiple viruses need to be differentiated in one assay to facilitate diagnosis and patient management.